EGFR and non-small cell lung carcinoma: We examined the effects of D3 with EGFR inhibitors on Hep3B, a hepatoma with wild-type EGFR37; PC-9 cells, a human non-small cell lung cancer (NSCLC) line with a EGFR activating exon 19 mutation38; and H1975, a NSCLC with EGFR L858R T790M mutations39.